Member Info for crumbs

I reckon Cliff will have a little bit to talk about and quite possibly will be even smiling ......

https://event.webinarjam.com/register/633/pyy7gsxmo

You mean today scancell was a good trading share and some pi will have made a few quids we will probably now have many such days as the good news flows from a fully funded scancell and more pi wake up to it.... what next the first of the Avidimab glycan deals maybe

What is exciting about the new peptide nanoparticle delivery vehicle for ImmunoBody is I think it seems to have been partly developed by scancell with UON.... so hopefully no need for a third-party product.... implications for SCIB2 and the CRUK funded trial maybe.... I certainly hope to hear more on this

AvidiMab and 5 Glycan Mabs with multiple cancer targets for each Glycan Mab and AvidiMab being of potential use to all MaBs .... the amount of potential deals there is massive and that is before we get to moditope and the potential deals there... remember modi1 it goes into trial in 4 targets! with a potential expansion into 15 on showing any success ... that it quite a nice spread of a chances .... followed by modi2 modi3...

I very much doubt Redmile or Vulpes or any of scancells ii ever consulted Trinity for a valuation estimate when they invested here (I know I don't pay any attention to their valuations one deal rips them up) which makes me think they are looking at scancell using their own risk/reward thinking.... Also, scancell already has one product of one pipeline that induced a beneficial immune response in late-stage cancer sufferers .... It is something that can't be gamed.... Lindy has form

'Don't worry it will only happen after about 7 or 8 billion years.' A scancell timeline that! :)

The delivery of COVIDITY (ImmunoBody) has to be an area we are waiting to hear more on .... is CRUK also waiting on it for SCIB2 for which a nano delivery route has been chosen as it does not seem any progress is happening there, hopefully we will hear more on that as we know getting that delivery right transforms the ImmunoBody platform to a more practical and also its attractiveness to third parties.

Like magic, my refund has just appeared too! :)

Ruck yeah poor show with the refund I'm still waiting too

https://money.cnn.com/quote/shareholders/shareholders.html?symb=BNTX&subView=institutional
Redmile are the second biggest stakeholders in BioNTech..... now again could be completely wrong but with the TCR collab being so far along you could surmise it must be going alright if Redmile talked to Sahin which again you would think they did before they invested here...... just a bit of 1+1 .... which is not always correct here lol.... also I wonder if Vulpes kindly let them in on their in depth pre investment research.... whatever they bought in!

The thing with Redmile is the BioNTech connection I think I am right in saying redmile are BioNTechs biggest ii backer (may be wrong there) certainly they must be one of them... anyways that you would think would give them access to Sahin and you would think a conversation would have taken place..... what you make of Lindy's work?..... Sahin he say......

I remember Cliff saying the first partner was going to look at all the MaBs and Avidimab in all their possible therapeutic potentials which when you look at the many possibilities of the MaBs -ICD ADC CAR-T Bispecifics In vivo and In vitro
TSCM expansion-means the partner has that tech capability

'signed its first collaboration and non-exclusive research agreement with a leading antibody technology company '

' Our first collaboration and evaluation agreement with one of the major players in the antibody development field is a significant achievement in such a short period of time and we believe our novel AvidiMab™ enhanced cell killing platform has
broad partnering potential."'

I think though yeah your right the wording has changed it could and probably is most likely the first collab partner.....Sounds like they could be the kind of name that would raise a few heads on revelation though.....and sp of course lol

It is to show the wheels are still turning and whereabouts they are, as since the last presentation a lot has happened so hopefully there will also be a new up to date PDF.... The amount of funds baby bio scancell has is still small beer however the size and scope of the pipeline is a potential big pharma

Which sounds like that first collab is going to plan so any deal will be done with at least year of looking closely in lab experimentation at the MaBs and Avidimab in all their potential ..... obviously, a deal after that would also be a great boost to the value of IP as that is a 3rd party saying yes we have tried and we have liked enough to do a deal it could also be a very interesting deal seeing at just how much potential there is in Avidimab and the glycans

Definitely or is it defiantly..... anyways the d word we need is deals;-)

With over 15 mill in the bank.... sit back relax :) the science is being seen potential deal/s to be done across 3 platforms and multiple products with an enviable amount of targets many of them the toughest ones and moditope can now be proven in human trials by scancell itself... risk-free no..... de-risked by....... dilution lol but done by getting in some impressive ii's -yes! ....

They are being looked at in depth with partners already :

' Scancell and its partner will evaluate the potential of anti-TaG mAbs, enhanced with AvidiMab™, in various formats including, antibody drug conjugates, bispecific antibodies, as well as stand-alone antibody products.'

The first of 3 of those partnerships was expected to have a year long collab looking in full depth that year began 4th Sept 2019
So....... the first deal/s may not be too far away

https://www.scancell.co.uk/Data/Sites/1/media/docspres/presentation-to-lsx-world-congress-february-2020.pdf

page 15
'Broad scope and utility ? multiple licensing opportunities '

5 MaBs good to go